thought call
look gilead strong perform address linger concern
regard durabl base hiv hcv franchis thought
import take-away call confid path growth follow
troughconsist thesi hiv biktarvi impress becom
top option experienc patient follow feb launch primarili captur
switch older regimen vs genvoyatrend earlier analysi predict
see gilead scienc hiv doc survey favor pt given
project biktarvi like becom lead fdc global bolster
stabil albeit declin hcv franchis continu see stabil head
addit long-term potenti upsid yescarta follow
commerci investmentsa well late-stag pipelin asset filgotinib
nash portfoliow see support gilead return growth stori
announc ceo john milligan step john martin later
date surpris fundament growth strategi emerg pipelin
nash filgotinib car-t much intact new leadership unlik alter
emerg compel stori biotech anoth pipelin deal liver
diseas heme/onc would addit growth given leadership chang
suspect less like near term maintain ow rate pt
pipelin updat approv yescarta eu anticip filgotinib
phase finch ra trial set start read later year poc phase
ankylos spondyl expect late earli phase data fxr agonist
nash pbc psc like data inhibitor lupu
adjust estim adjust forecast increas hiv
revenu off-set declin hcv respect
result forecast total revenu revis opex tax
estim estim ep
quarterli annual ep usd
consensu number thomson reuter receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
return equiti ttm
link barclay live interact chart
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
overweight gilead move beyond
declin hcv franchis diversifi
oncolog car-t creat intermedi term
visibl could return growth hiv
stabl bictegravir potenti drive
share gain car-t earli stage technolog
hematolog expans solid tumor ad
valu
modest declin hcv robust uptak
taf regimen hiv pipelin success non-
virolog agent larg discount share
would drive upsid de-risk axi-cel addit
hematolog success solid tumor
price pressur drive faster declin hcv
diminish cash flow therebi affect abil
busi develop hiv gener
larger impact expect new taf regimen
experi limit uptak car-t fail expand
geoff meacham ph herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli
relat specif recommend view express research report
barclay research produc invest bank barclay bank plc affili collect individu barclay
avail disclosur
compani subject research report current import disclosur regard compani pleas refer
http //publicresearch barclay com altern send written request barclay research complianc seventh avenu floor
new york ny call
analyst respons prepar research report receiv compens base upon variou factor includ firm total
revenu portion gener invest bank activ profit revenu market busi
potenti interest firm invest client research respect asset class cover analyst
author contribut research report research analyst unless otherwis indic
public date top report reflect local time report produc may differ releas date provid
gmt
analyst regularli conduct site visit view materi oper cover compani barclay polici prohibit accept
payment reimburs cover compani travel expens visit
http //publicresearch barcap com/s/rd htm order access barclay research conflict manag polici statement pleas refer
procedur pleas
barclay research depart produc variou type research includ limit fundament analysi equity-link analysi
quantit analysi trade idea recommend contain one type barclay research may differ contain
type barclay research whether result differ time horizon methodolog otherwis barclay research depart
oper independ absa research depart absa research produc absa bank limit act corpor
invest bank divis part barclay africa group limit affili invest bank barclay bank plc elig
client may receiv research report research depart may reach differ conclus may contain differ
conflict forecast recommend trade idea
price sourc thomson reuter last avail close price relev trade market unless anoth time sourc
